Trends in first‐trimester nausea and vomiting of pregnancy and use of select treatments: Findings from the National Birth Defects Prevention Study
| Autor: | Nedghie Adrien, Nina L. Schrager, Carla M. Van Bennekom, Allen A. Mitchell, Samantha E. Parker, Martha M. Werler |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Metoclopramide Vomiting Epidemiology Nausea Population Article Ondansetron 03 medical and health sciences 0302 clinical medicine Pregnancy immune system diseases Morning sickness Humans Medicine 030212 general & internal medicine education education.field_of_study 030219 obstetrics & reproductive medicine business.industry Obstetrics Infant virus diseases Prochlorperazine medicine.disease Pregnancy Complications Pregnancy Trimester First Case-Control Studies Pediatrics Perinatology and Child Health Antiemetics Female medicine.symptom business medicine.drug |
| Zdroj: | Paediatr Perinat Epidemiol |
| ISSN: | 1365-3016 0269-5022 |
| DOI: | 10.1111/ppe.12705 |
| Popis: | BACKGROUND: Although nausea and vomiting of pregnancy (NVP) is common, the secular and demographic trends of NVP and its treatments are not well-studied. OBJECTIVES: To describe the prevalence and patterns of first-trimester NVP and selected treatments among controls in the National Birth Defects Prevention Study (NBDPS). METHODS: National Birth Defects Prevention Study is a population-based case–control study of birth defects in the United States (1997-2011). We collected self-reported data about NVP and use of commonly reported pharmacological and herbal/natural treatments (ondansetron, promethazine, pyridoxine, metoclopramide, doxylamine succinate, ginger, phosphorated carbohydrate solution, and prochlorperazine) from mothers of non-malformed control infants. We estimated the prevalence of NVP and selected treatments and examined secular and demographic trends (education, race/ethnicity, and maternal age) for such use, adjusting for study centre. RESULTS: Among 10 540 mothers of controls, 7393 women (70.1%) reported first-trimester NVP, and 12.2% of those used one or more of the commonly reported treatments. Specific treatment use varied after adjustment for study centre (ondansetron: 3.4%; promethazine: 4.2%; pyridoxine: 3.2%; metoclopramide: 0.7%; doxylamine succinate: 1.7%; ginger: 1.0%; phosphorated carbohydrate solution: 0.4%; and prochlorperazine: 0.3%). Treatment use increased for each agent over the study period. Women with more years of education reported more NVP and treatment use. White (72%), Hispanic (71%), and other race (73%) women reported more NVP than Black women (67%); White women used selected NVP treatments most frequently, and Black women used them more than Hispanic women. Though women aged 25-34 years reported more NVP (72%) than younger (69%) or older (67%) women, the frequency of medication use was similar among women aged 25-34 and ≥35, and lower among women aged |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|